Ajanta Pharma Ltd's Q3FY25 Quarter Results
- 31 Jan 2025
Result Summary
- Ajanta Pharma Ltd reported a 2.5% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 5.2%.
- Its expenses for the quarter were down by 5.1% QoQ and up 5.0% YoY.
- The net profit increased 7.6% QoQ and increased 10.9% YoY.
- The earnings per share (EPS) of Ajanta Pharma Ltd stood at 18.6 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 1176.57 | 1206.12 | 1118.74 | -2.5% | 5.2% |
Total Expenses | 869.18 | 915.88 | 827.83 | -5.1% | 5.0% |
Profit Before Tax | 307.39 | 290.24 | 290.91 | 5.9% | 5.7% |
Tax | 74.51 | 73.76 | 80.88 | 1.0% | -7.9% |
Profit After Tax | 232.88 | 216.48 | 210.03 | 7.6% | 10.9% |
Earnings Per Share | 18.60 | 17.30 | 16.70 | 7.5% | 11.4% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Ajanta Pharma Ltd is a well-established pharmaceutical company that operates primarily in the healthcare sector. The company is known for its production and distribution of a wide range of pharmaceutical products, including generic and branded formulations. Ajanta Pharma has a significant presence in both domestic and international markets, with a strong focus on research and development to drive innovation in its product offerings. The company operates in a highly competitive industry that is subject to regulatory changes and market dynamics. Recent developments in the company may include expansions in its product line, strategic partnerships, or advancements in manufacturing capabilities, although specific details are not available.
Revenue
During the third quarter of fiscal year 2025 (Q3FY25), Ajanta Pharma Ltd reported a total income of ₹1176.57 crores, showing a slight decrease of 2.5% compared to the previous quarter (Q2FY25) where the total income was ₹1206.12 crores. However, when compared to the same period in the previous fiscal year (Q3FY24), the total income increased by 5.2% from ₹1118.74 crores. This year-over-year growth in total income indicates a positive revenue trend for the company over the past year. The quarter-over-quarter decline may reflect seasonal variations, market conditions, or other external factors affecting revenue generation during this period.
Profitability
Ajanta Pharma Ltd's profitability metrics for Q3FY25 demonstrate an improvement over both the previous quarter and the same quarter in the previous year. The company achieved a profit before tax (PBT) of ₹307.39 crores, marking an increase of 5.9% from Q2FY25's PBT of ₹290.24 crores, and a 5.7% increase from Q3FY24's PBT of ₹290.91 crores. The profit after tax (PAT) for Q3FY25 was reported at ₹232.88 crores, which is 7.6% higher than the PAT of ₹216.48 crores in Q2FY25 and 10.9% higher than the PAT of ₹210.03 crores in Q3FY24. Earnings per share (EPS) also rose to ₹18.60 in Q3FY25, up from ₹17.30 in Q2FY25 and ₹16.70 in Q3FY24, indicating an upward trend in shareholder returns on a per-share basis.
Operating Metrics
Ajanta Pharma Ltd managed to reduce its total expenses in Q3FY25 to ₹869.18 crores, a decrease of 5.1% from Q2FY25's total expenses of ₹915.88 crores. Compared to Q3FY24, where total expenses were ₹827.83 crores, there is a year-over-year increase of 5.0%. The tax expenses for Q3FY25 were ₹74.51 crores, which is slightly higher by 1.0% than the tax expenses in Q2FY25 of ₹73.76 crores, but lower by 7.9% compared to Q3FY24's tax expenses of ₹80.88 crores. The operational efficiency and cost management strategies seem to be impacting the company's financial performance, as evidenced by the reduction in quarterly expenses and fluctuations in tax obligations. This financial period's operational metrics highlight a focus on maintaining profitability through controlling costs while supporting revenue growth.
